These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35049423)

  • 1. Antibody response in patients with autoimmune inflammatory rheumatic disease after pneumococcal polysaccharide prime vaccination or revaccination.
    Rasmussen SL; Strandbygaard LL; Fuursted K; Kragholm KH; Leutscher P; Rasmussen C
    Scand J Rheumatol; 2023 Mar; 52(2):174-180. PubMed ID: 35049423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.
    Nived P; Jönsson G; Settergren B; Einarsson J; Olofsson T; Jørgensen CS; Skattum L; Kapetanovic MC
    Arthritis Res Ther; 2020 Feb; 22(1):36. PubMed ID: 32087733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial.
    Nguyen MTT; Lindegaard H; Hendricks O; Jørgensen CS; Kantsø B; Friis-Møller N
    J Rheumatol; 2017 Dec; 44(12):1794-1803. PubMed ID: 28966211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
    Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above].
    Ma QL; Zhang M; Liu LJ; Zhou Y; Yuan W; Yang M; Liu SX; Luo LY; Chen HP; Xiao YH; Qi Q; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jul; 44(7):1119-1125. PubMed ID: 37482716
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status.
    Rasmussen SL; Fuursted K; Nielsen KA; Laurberg NP; Sørensen MB; Fagerberg SK; Leutscher P; Rasmussen C
    Scand J Rheumatol; 2020 Sep; 49(5):353-360. PubMed ID: 32468899
    [No Abstract]   [Full Text] [Related]  

  • 7. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
    Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
    Alten R; Bingham CO; Cohen SB; Curtis JR; Kelly S; Wong D; Genovese MC
    BMC Musculoskelet Disord; 2016 May; 17():231. PubMed ID: 27229685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.
    Crnkic Kapetanovic M; Saxne T; Truedsson L; Geborek P
    Arthritis Res Ther; 2013 Jan; 15(1):R1. PubMed ID: 23286772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study.
    Guo X; Li J; Qiu J; Zhang R; Ren J; Huang Z; Li Z; Liang X; Lan F; Chen J; Huang F; Sun X
    Expert Rev Vaccines; 2024; 23(1):237-245. PubMed ID: 38369970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
    Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
    Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to pneumococcal conjugate and polysaccharide vaccination in children with rheumatic disease.
    Jensen L; Christensen AE; Nielsen S; Pedersen FK; Rosthøj S; Jørgensen CS; Poulsen A
    Scand J Immunol; 2022 Feb; 95(2):e13118. PubMed ID: 34768311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.
    Mori S; Ueki Y; Akeda Y; Hirakata N; Oribe M; Shiohira Y; Hidaka T; Oishi K
    Ann Rheum Dis; 2013 Aug; 72(8):1362-6. PubMed ID: 23345600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
    Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
    Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.